explore -WSS

explore

author：focus 2025-09-30 18:20:40 - browse：3912

Chris O'Meara/AP

Johnson & Johnson faces a consequential new class action lawsuit — not in its role as a manufacturer of drugs, but as an employer and purchaser of prescription drugs for its workers.

Ann Lewandowski, a health care policy and advocacy director at J&J, sued her company on Monday for allegedly overpaying its pharmacy benefit manager for its employees’ medicines, citing previous STAT reporting to support some of the allegations. Those overpayments, the lawsuit alleges, ultimately come out of workers’ paychecks in the form of high health insurance premiums, higher out-of-pocket drug costs, and stunted wage growth.

In one example, J&J allegedly paid its PBM more than $10,000 for a single 90-day prescription of teriflunomide, a generic medicine for multiple sclerosis, when that same 90-day prescription could be purchased for as little as $30 elsewhere without insurance, according to the lawsuit.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： What do new weight loss drugs mean for bariatric surgery?

entertainment

WSS

How to make Best Hospitals ratings actually useful for patients

Radiation, mainstay of cancer treatment, begins a fade

Chan Zuckerberg Biohub Chicago to focus on inflammation

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Neuroscience startup Neumora files for IPO

Psilocybin's anti

knowledge

explore

leisure time

Duchenne breakthrough therapy leaves behind pioneering families

Why Charlie Gard's case is so disturbing to Americans

Tori Bowie and the unacceptable rates of Black maternal death

FDA rejects Alnylam's heart disease treatment over insufficient data

George Santos makes 1st court appearance after pleading not guilty to 13 counts

How to make AI work for medicine

Anesthesiologist group: stop taking Ozempic before surgery

Apellis safety probe of eye disease drug centers on injection needle

Drug repurposing or repositioning? The language matters

Bill would stop addiction treatment from triggering child abuse inquiry

Wikipedia

Why Charlie Gard's case is so disturbing to Americans

Analysis of telehealth claims data suggest service duplication

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

2024 GOP presidential candidates spar over abortion in debate

Sana to lay off nearly a third of staff, de

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

explore

focus

entertainment

hotspot